-
Charlie Puth and Ellie Goulding to Headline First Johnnie & Co. Festival in Mumbai
-
ALIX LASERS shareholders remove Michael Sobitsch as managing director in view of the circumstances
-
Maryland Woman Arrested in Decade-Long Cancer Scam Involving Fake Medical Team
-
Panthers Seek NFC South Lead Against Ravens as Baltimore Ends Skid
-
Arrive AI's Pro Forma Stockholders' Equity Now Above Nasdaq Minimum Requirement Following Recent Transactions
-
5 Fun Date Night Ideas That Don't Cost a Fortune
-
The DEA Laid The Trap - And State Marijuana Operators Took The Bait
-
Tosca's 2026 Sustainability Report Makes the Case for Packaging as Critical Supply Chain Infrastructure
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 20
-
Ryde Group Ltd Announces Non-Binding Term Sheet for Proposed Minority Investment in Multi Genius Limited and MOU on Technology Collaboration
-
American Resources Corporation and ReElement Technologies Selected as Part of Winning U.S.-Led Consortium for Kenya's Strategic Mrima Hill Critical Minerals Project
-
barq Signs MoU with TenPay Global to Enhance Remittances and Digital Payments in China
-
Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
-
Alset AI Closes Non-Brokered Private Placement Offering
-
PodcastOne (NASDAQ:PODC) Launches People Pleasers Podcast hosted by Comedians Leah Rudick and Jessica Michelle Singleton
-
Who Does the Best Rhinoplasty in Sarasota?
-
AI Search Engineers Says Longer AI Mode Questions Mean Professional Service Firms Should Answer Full Client Questions Directly on Their Pages
-
American Businessman Mark Eric Williams Vindicated in Six-Year, US$150 Million-Plus Litigation Brought by Kuwaiti State Entities
-
Dateline appoints Tony Ferguson as Acting Chairman
-
Closing a Business with Payroll Taxes Owed - Clear Start Tax Explains the Trust Fund Recovery Penalty
-
AsiaFIN Holdings Corp. Appoints Fortune Angel INC as U.S. Reseller Partner to Expand Its Agentic and Robotic Process Automation SaaS Business Across New York and the East Coast
-
Cytta Air Expands Military Contracting Expertise - Appoints Rear Admiral James "Gib" Godwin III to Advisory Board
-
Ondas, Palantir and Regna AI Host Key Defense Technology Leaders to Accelerate the Path from AI Innovation to Fielded Capability
-
Taylor Bank Announces $125,000 Commitment to Diakonia's Supportive Living Campus Capital Campaign
-
enVVeno Medical Presents Three-Year Surgical Venous Valve Replacement Data Showing Sustained Clinical Benefit and Highlights Next-Generation enVVe Transcatheter System at the 53rd Annual VEITH Symposium
-
First Phosphate and Zeo Energy Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
Kartoon Studios' Beacon Media Partners With Bandai on Tamagotchi's Landmark 30th Anniversary Times Square Celebration
-
Jaguar Health, Inc. Announces Reverse Stock Split
-
Commonhold Explained: How New Leasehold Ban Changes Property Ownership in England and Wales
-
Factory Worker Dies in Rare Rectal Explosion Incident in Czechia
-
GIRLBAND! Headline Show at Rough Trade Marks National Breakthrough
-
Decoding UNFCCC Legal Language: The Hierarchy of Verbs in Climate Negotiations
Biden's DEA Wall of Marijuana Dishonor: The DEA Pattern of Corruption Is Now Impossible to Deny, President Trump Fixing
Now, President Trump is poised to fix the marijuana rescheduling issue.
From DEA unconstitutional tribunals to Anne Milgram swamp contracts and MMJ BioPharma's seven year clinical trial delays, the DEA's Diversion leaders built an illegal fortress of obstruction around medical cannabis.
WASHINGTON, D.C., AL / ACCESS Newswire / October 18, 2025 / For decades, the Drug Enforcement Administration (DEA) preached "law and order."
But behind the curtain of press releases and public hearings lay a very different reality - one defined by unconstitutional procedures, ethical breaches, and bureaucratic cruelty that left patients with Huntington's Disease and Multiple Sclerosis waiting years for medicine that Congress already legalized.
The DEA Wall of Marijuana Dishonor has collapsed under its own corruption.

Action 1: The Catch-22 - Matthew Strait's FOR EVER changing Impossible Rules
What they said: "Follow the rules and you'll be approved."
What they did: Matthew Strait, former Deputy Assistant Administrator, invented a "bona fide supply agreement" requirement years after cannabis research applications were filed - a retroactive trap that made lawful registration impossible.
The proof: DEA-registered companies that followed every federal law were blocked, while illegal state markets flourished unchecked.
Action 2: The Unconstitutional Tribunals - DEA Aarathi Haig's Legal Disaster
What they said: "We operate under proper legal procedures."
What they did: DEA attorney Aarathi Haig defended the agency's in-house court system even after the Supreme Court ruled it unconstitutional in Axon v. FTC (2023) and Jarkesy v. SEC (2024).
The proof: The Department of Justice itself withdrew its defense of DEA's tribunal structure, acknowledging it violated Article II and the separation of powers - yet Haig and her colleagues kept using it.
Action 3: The Ethical Collapse - Aarathi Haig's NJ Law Bar Trouble
What they said: "We maintain the highest standards."
What they did: Haig continued practicing law for DEA while not in good standing with the New Jersey Bar, as verified by state records.
The proof: A February 14, 2023 letter from the New Jersey Board of Bar Examiners confirms Haig was ineligible for a Certificate of Good Standing for failing to pay mandatory fees, complete continuing education, and maintain IOLTA compliance - in direct violation of 28 U.S.C. § 530B, which requires federal attorneys to adhere to state ethics rules.
Action 4: The Swamp Contracts - DEA Anne Milgram's Crony Network
What they said: "We are responsible stewards of taxpayer dollars."
What they did: Former DEA Administrator Anne Milgram handed out millions in no-bid contracts to friends and former colleagues, prompting an ongoing DOJ Inspector General investigation.
The proof: Congressional records and whistleblower accounts reveal a pattern of insider payments and conflict of interest - all while Milgram ignored DEA's core mission of enforcing the law and advancing legitimate research.
Action 5: The Seven-Year Stonewall - DEA Thomas Prevoznik's Delay Machine
What they said: "We process applications in a timely manner."
What they did: Thomas Prevoznik's division has stalled MMJ BioPharma's cannabis manufacturing application since 2018 - despite FDA Investigational New Drug (IND) approval and Orphan Drug designations for its Huntington's and Multiple Sclerosis treatments.
Patients with degenerative neurological diseases have been forced to wait as their conditions worsen - victims of bureaucratic negligence masquerading as procedure.
While these officials - Strait, Haig, Milgram, and Prevoznik - publicly celebrated "science-based regulation," their internal actions revealed something darker:
An unconstitutional court system run by agency insiders
An impossible regulatory maze designed to fail applicants
An ethical swamp of self-dealing and crony contracts
A seven-year blockade on federally legal medicine
Their exits tell the real story:
Matthew Strait - retired under scrutiny.
Anne Milgram - resigned amid federal investigation.
Thomas Prevoznik - quietly retiring under scrutiny.
Aarathi Haig - ethically compromised and professionally tainted.
They weren't reforming the system - they were fleeing it.
Patients Still Waiting. But Not for Long.
The real victims of the DEA's misconduct aren't the bureaucrats or the politicians - they're the patients living with Huntington's Disease and Multiple Sclerosis, whose suffering has been prolonged by regulatory malpractice.
"We've lost seven years - seven years of potential progress, of clinical data, of human hope," Boise said. "But the tide is finally turning."
The Turning Point: President Trump's Administration
As the Trump Administration continues its overhaul of the Justice Department and DEA, patient advocates are confident the White House will take decisive action.
President Trump has repeatedly pledged to put patients and science first, signaling his intention to clear the DEA backlog and restore lawful, evidence-based decision-making to medical cannabis research.
The Bottom Line
The DEA's "Wall of Marijuana Dishonor" is cracking under the weight of its own corruption.
Its architects have fled. Its constitutional foundation has collapsed.
And its legacy - obstruction, hypocrisy, and human suffering - will be remembered as a stain on American medicine.
But MMJ BioPharma remains.
Fully compliant. Fully lawful. Fully ready to lead the next chapter of pharmaceutical cannabis - one defined not by politics, but by patients, science, and justice.
About MMJ BioPharma Cultivation
MMJ BioPharma Cultivation, a subsidiary of MMJ International Holdings, develops pharmaceutical-grade cannabinoid formulations for FDA-regulated clinical trials targeting Huntington's Disease and Multiple Sclerosis.
The company holds Orphan Drug Designations and multiple IND filings, positioning itself as the first federally compliant producer of standardized cannabinoid medicine for neurological disorders.
MMJ is represented by attorney Megan Sheehan.
CONTACT:
Madison Hisey
[email protected]
203-231-8583
SOURCE: MMJ International Holdings
View the original press release on ACCESS Newswire
D.Lopez--AT